Cargando…

Enhancement of the anti-tumour effect of cyclophosphamide by the bioreductive drugs AQ4N and tirapazamine

The ability of the bioreductive drugs AQ4N and tirapazamine to enhance the anti-tumour effect of cyclophosphamide was assessed in three murine tumour models. In male BDF mice implanted with the T50/80 mammary carcinoma, AQ4N (50–150 mg kg(−1)) in combination with cyclophosphamide (100 mg kg(−1)) pro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Friery, O P, Gallagher, R, Murray, M M, Hughes, C M, Galligan, E S, McIntyre, I A, Patterson, L H, Hirst, D G, McKeown, S R
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2000
Materias:	Regular Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363362/ https://www.ncbi.nlm.nih.gov/pubmed/10780528 http://dx.doi.org/10.1054/bjoc.1999.1132

Ejemplares similares

The chemopotentiation of cisplatin by the novel bioreductive drug AQ4N
por: Gallagher, R, et al.
Publicado: (2001)

The chemopotentiation of cisplatin by the novel bioreductive drug AQ4N
por: Gallagher, R, et al.
Publicado: (2002)

DNA damage following combination of radiation with the bioreductive drug AQ4N: possible selective toxicity to oxic and hypoxic tumour cells.
por: Hejmadi, M. V., et al.
Publicado: (1996)

Enhancement of chemotherapy and radiotherapy of murine tumours by AQ4N, a bioreductively activated anti-tumour agent
por: Patterson, L H, et al.
Publicado: (2000)

AQ4N: an alkylaminoanthraquinone N-oxide showing bioreductive potential and positive interaction with radiation in vivo.
por: McKeown, S. R., et al.
Publicado: (1995)

Importance of P450 reductase activity in determining sensitivity of breast tumour cells to the bioreductive drug, tirapazamine (SR 4233).
por: Patterson, A. V., et al.
Publicado: (1995)

AQ4N: a new approach to hypoxia-activated cancer chemotherapy
por: Patterson, L H, et al.
Publicado: (2000)

Detection of hypoxia by measurement of DNA damage in individual cells from spheroids and murine tumours exposed to bioreductive drugs. I. Tirapazamine.
por: Olive, P. L.
Publicado: (1995)

Effects of Bioreductive Agents, Tirapazamine and Mitomycin C, on Quiescent Cell Populations in Solid Tumors, Evaluated by Micronucleus Assay
por: Masunaga, Shin‐ichiro, et al.
Publicado: (1997)

Cisplatin anti-tumour potentiation by tirapazamine results from a hypoxia-dependent cellular sensitization to cisplatin
por: Kovacs, M S, et al.
Publicado: (1999)

Radiosensitization of hypoxic tumour cells by S-nitroso-N-acetylpenicillamine implicates a bioreductive mechanism of nitric oxide generation
por: Janssens, M Y, et al.
Publicado: (1999)

Exploiting tumour hypoxia and overcoming mutant p53 with tirapazamine.
por: Brown, J. M.
Publicado: (1998)

Does reductive metabolism predict response to tirapazamine (SR 4233) in human non-small-cell lung cancer cell lines?
por: Chinje, E C, et al.
Publicado: (1999)

Tirapazamine-cisplatin: the synergy.
por: Gatzemeier, U., et al.
Publicado: (1998)

Bioreductive drugs and the selective induction of tumour hypoxia.
por: Bremner, J. C., et al.
Publicado: (1990)

Case of Poisoning by Aq. Ammonia
por: Patterson, A.
Publicado: (1857)

Metabolism of the bioreductive cytotoxin SR 4233 by tumour cells: enzymatic studies.
por: Wang, J., et al.
Publicado: (1993)

The effect of recombinant human erythropoietin treatment on tumour radiosensitivity and cancer-associated anaemia in the mouse.
por: Joiner, B., et al.
Publicado: (1993)

NADPH:cytochrome c (P450) reductase activates tirapazamine (SR4233) to restore hypoxic and oxic cytotoxicity in an aerobic resistant derivative of the A549 lung cancer cell line
por: Saunders, M P, et al.
Publicado: (2000)

SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours.
por: Brown, J. M.
Publicado: (1993)

The effect of tirapazamine (SR-4233) alone or combined with chemotherapeutic agents on xenografted human tumours.
por: Lartigau, E., et al.
Publicado: (1996)

Introduction to the AQ-WATCH Project and the AQ-WATCH Toolkit to fight air pollution
por: Li, C, et al.
Publicado: (2022)

Potential use of the alkaline comet assay as a predictor of bladder tumour response to radiation
por: McKeown, S R, et al.
Publicado: (2003)

Subcellular Location of Tirapazamine Reduction Dramatically Affects Aerobic but Not Anoxic Cytotoxicity
por: Guise, Chris P., et al.
Publicado: (2020)

Enhancing effect of misonidazole on the response of the RIF-1 tumour to cyclophosphamide.
por: Law, M. P., et al.
Publicado: (1981)

Assessment of NO(2) observations during DISCOVER-AQ and KORUS-AQ field campaigns
por: Choi, Sungyeon, et al.
Publicado: (2020)

Toward Hypoxia-Selective DNA-Alkylating Agents Built by Grafting Nitrogen Mustards onto the Bioreductively Activated, Hypoxia-Selective DNA-Oxidizing Agent 3-Amino-1,2,4-benzotriazine 1,4-Dioxide (Tirapazamine)
por: Johnson, Kevin M., et al.
Publicado: (2014)

Electronic structure and reactivity of tirapazamine as a radiosensitizer
por: Romero, José, et al.
Publicado: (2021)

Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia
por: Guise, Christopher P., et al.
Publicado: (2014)

Preclinical efficacy of the bioreductive alkylating agent RH1 against paediatric tumours
por: Hussein, D, et al.
Publicado: (2009)

Targeting DNA topoisomerase IIα (TOP2A) in the hypoxic tumour microenvironment using unidirectional hypoxia‐activated prodrugs (uHAPs)
por: Smith, Paul J., et al.
Publicado: (2022)

Activation of Distinct α(5)β(1)-mediated Signaling Pathways by Fibronectin's Cell Adhesion and Matrix Assembly Domains
por: Hocking, Denise C., et al.
Publicado: (1998)

Applicability of Combination with Tirapazamine in Boron Neutron Capture Therapy
por: Masunaga, Shin‐ichiro, et al.
Publicado: (1998)

Development and Validation of a Kilogram-Scale Synthesis of Tirapazamine
por: Lienard, Philippe, et al.
Publicado: (2020)

Tirapazamine-induced DNA damage measured using the comet assay correlates with cytotoxicity towards hypoxic tumour cells in vitro.
por: Siim, B. G., et al.
Publicado: (1996)

Enhancement of bioreductive drug toxicity in murine tumours by inhibition of the activity of nitric oxide synthase.
por: Butler, S. A., et al.
Publicado: (1997)

Pharmacokinetics and binding of the bioreductive probe for hypoxia, NITP: effect of route of administration.
por: Hodgkiss, R. J., et al.
Publicado: (1995)

Changes in the Sensitivity of Intratumor Cells during Fractionated Tirapazamine Administration
por: Masunaga, Shin‐ichiro, et al.
Publicado: (2000)

Redox Proteomic Profile of Tirapazamine-Resistant Murine Hepatoma Cells
por: Nemeikaitė-Čėnienė, Aušra, et al.
Publicado: (2023)

Antibody-Based Imaging of Bioreductive Prodrug Release in Hypoxia
por: Tosun, Çağla, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_km4gkgaceds8aah4jml9l5igvb